Introduction Surgical resection is the only curative treatment for pancreatic neuroendocrine tumors (PNETs), but pancreatic operations carry a significant morbidity. We investigated whether the resection of small, asymptomatic nonfunctioning PNETs is beneficial. Clinicopathologic factors were retrospectively reviewed for all PNET cases from 1998 to 2014. Methods Kaplan-Meier survival and multivariable regression analyses were performed. A total of 249 patients had nonfunctioning PNETs with adequate follow-up, of whom 193 were resected and 56 were observed. Median age was 56 years, and 48 % of the patients were female. Results Overall, the resected patients had a significantly longer survival (OS) (p = 0.001). However, for the patients with PNETs ≤2.5 cm in size and without metastasis at presentation, tumor size significantly modified the effect of resection on overall survival (p < 0.05). The protective effect of resection increased as tumor size increased. An operation became a significant predictor of overall survival for tumors >1.5 cm (p = 0.050 or less for larger tumors) but was not significant for tumors <1.5 cm (p = 0.317 or more for smaller tumors), controlling for age-adjusted Charlson comorbidity index. Conclusion Resection of nonfunctioning PNETs over 1.5 cm is independently and significantly associated with a longer survival. However, the benefit of resection for tumors under 1.5 cm is unclear.
Introduction
Pancreatic neuroendocrine tumors (PNETs) are rare malignancies originating from pancreatic islet cells. In 2015, an estimated 1900 new cases of PNET will be diagnosed in the USA, 1 though autopsy studies indicate that many more undiagnosed cases may occur, affecting up to 0.8-10 % of the population.
2 , 3 PNETs are broadly divided into functioning tumors, which cause symptoms through the abnormal secretion of hormones, and nonfunctioning tumors, which do not secrete hormones. An estimated 68-80 % of all PNETs are nonfunctioning, 4 -7 and patients with nonfunctioning tumors have been reported to have poorer outcomes than those with functioning tumors. 8 In recent years, improved and more frequent radiologic imaging has led to the identification of increasingly smaller and earlier stage PNETs, as well as a marked increase in diagnosed cases overall. 9 With this, the question of their optimal management has come under increased scrutiny.
Surgical resection is the only curative treatment available for PNETs. Indeed, with the increased diagnosis of PNETs, a concomitant increase in surgically resected cases has been observed over the past three decades. 10 However, despite improvements in surgical outcomes, pancreatic operations still carry a significant morbidity, with up to a 44 % complication rate. 11 While functioning PNETs are generally resected due to their symptomatic presentation, the appropriate management for nonfunctioning tumors is less clear. Since PNETs are heterogeneous tumors with uncertain malignant potential and varied growth rates, it is difficult to predict for which patients an operation will offer a therapeutic benefit.
As tumor size has been widely shown to correlate with malignant behavior, 12 , 13 and the combination of tumor size, metastasis, and grade has been shown to provide accurate prognostic information, 14 the current consensus is that large PNETs should be surgically resected. 13 However, no guidelines have been established for observation versus resection when small, asymptomatic, nonfunctioning PNETs are identified. Larger populational studies have found that surgical resection is associated with a significantly longer overall survival for all PNET patients, 15 as well as specifically for patients with PNETs ≤2 cm. 16 This contrasts with a recent single institutional study that small PNETs ≤1.5 cm can be safely observed with little risk of metastasis. 17 On the other hand, our own single institutional study of resected PNET cases between 1977 and 2010 found that while tumors <2 cm in size were much less likely to have disease progression or metastasis following resection, a small number of patients with resected tumors under 2 cm experienced recurrence, metastasis, and death. 11 Given the limited and equivocal evidence, it remains an open question as to whether small, nonfunctioning PNETs should be resected or not.
The aim of this study was to investigate the conditions under which surgical resection of a nonfunctioning PNET offers patients a significant long-term benefit. Specifically, the first aim was to determine at what size a nonfunctioning PNET should be resected to confer a survival benefit. The second aim was to identify prognostic criteria that significantly affect whether surgical resection improves overall and disease-specific survival.
Materials and Methods
Data for this study were collected by retrospective chart review of patients who presented to our institution in their normal course of care, with approval from the institutional human research review committee.
Study Population
Patients with a pancreatic neuroendocrine tumor were identified by an institution-wide query for ICD-9 diagnosis codes 157.4 (malignant neoplasm of the islets of Langerhans) and 211.7 (benign neoplasm of the islets of Langerhans) and from a departmental database of operative PNET cases. The study population was limited to patients who presented to our institution between January 1, 1998, and March 31, 2014, and who were age 18 or older at presentation. Chart review was conducted to confirm the diagnosis of a nonfunctioning PNET and to collect clinicopathologic information. For the patients who underwent surgical resection, the PNET diagnosis was confirmed by pathology, while the observed patients were diagnosed with PNET by clinical and radiological features, and 35 of them had the PNET confirmed by fine needle biopsy. The patients with a clinical or pathological diagnosis of a functioning PNET with hormone secretion were excluded. Additionally, the patients who had an operation needed to have at least one post-operative follow-up encounter, while the patients who were observed needed to have at least one follow-up imaging study after their initial presentation to be included in this study.
Tumor size for the nonoperative patients was recorded from the radiology report at the time of diagnosis and for the resected patients from the surgical pathology report. Overall survival was calculated from the date of PNET diagnosis to the date of death or the last encounter or correspondence from the patients if they survived to the end of the study period. Deaths were recorded from the U.S. Social Security Death Index based on name, date of birth, and social security numbers. The cause of death was determined from notes and autopsy reports in the patients' charts. Only confirmed deaths by PNET, based on chart notes and autopsy records, were included in calculations of disease-specific survival.
Statistical Analysis
Kaplan-Meier survival curves were used to compare the survival of the patients in operative and nonoperative groups. Statistical significance was assessed by the log-rank test. Cox proportional hazard models were used to identify potential prognostic factors associated with survival in the nonoperative and operative patients. A two-sided p value of 0.05 was considered statistically significant. Cox multivariate proportional hazard models were used to identify the effect of an operation controlling for certain clinicopathologic characteristics. The effect modification of tumor size on an operation was identified through Cox proportional hazard models allowing the interaction term between an operation and tumor size. All statistical analyses were performed with Statistical Analysis Software (SAS), version 9.3.
Results

Clinicopathologic Characteristics
A total of 420 cases of PNET were identified. Functioning tumors were diagnosed in 96 patients. Of the 324 patients with nonfunctioning PNETs, 249 patients had adequate follow-up for inclusion in our study. Among them, 193 patients underwent surgical resection and 56 were observed over the follow-up period. The median age was 56 years (range 18 to 90), 48 % of patients were female, and 88 % of patients were white. Most of the patients had an isolated PNET with no history of prior endocrine neoplasias, though 7 patients had VHL disease and 23 patients had multiple endocrine neoplasia (MEN) type 1. The patients varied in terms of comorbidity burden, as the age-adjusted Charlson comorbidity index (CACI) ranged from 0 to 13, with a median value of 3. Small PNETs were well represented among this population: in the nonoperative group, 38 patients had a tumor ≤2 cm, while in the surgically resected group, 61 patients had a tumor ≤2 cm. Across all patient groups, the median follow-up time was 57 months. Patient demographics for each group are detailed in Table 1 .
Overall Survival and Disease-Free Survival
To compare trends in overall survival between the operative and nonoperative patients, a Kaplan-Meier survival analysis was conducted. As a group, the patients who underwent surgical resection had a significantly longer overall survival than the nonoperative patients (p = 0.001). This survival advantage was present at 2, 5, and 10 years and became increasingly pronounced over time. At 10 years after presentation, the operative group had a survival rate of 82.6 %, whereas the nonoperative group had a 53.7 % survival rate. In both groups, more than half of the patients survived until the end of the follow-up period. The Kaplan-Meier curves illustrating overall survival of each cohort are shown in Fig. 1 . The operative and nonoperative groups of patients were similar in terms of their comorbidity burden, as the median CACI at presentation was 4.0 among the nonoperative patients and 3.0 among the patients who underwent surgical resection. However, a greater proportion of the observed patients presented with distant metastasis from the PNET: 25 % compared to 7 % of resected cases.
Prognostic Factors for Overall Survival
To identify factors that predict favorable operative and nonoperative courses, clinicopathologic and treatment-related variables were tested for association with overall survival by univariate and multivariate regression models. The results are summarized in Tables 2 and 3 . In the nonoperative group, metastasis at any time during follow-up was the only significant predictor of overall survival in univariate and multivariate analyses (p = 0.004). The mean growth rate of tumors in the observed patients was 0.15 cm per year (range 0 to 9 cm per year), as calculated by sequential size measurements at follow-ups; tumor growth rate did not, however, reach significance in predicting survival within the observed group. There were also three patients who were initially observed and later resected: they were categorized into the resection group, and each had the resection 1-2 years after initial diagnosis and had tumor growth of about 1 cm in that time frame. Among the patients who underwent surgical resection, the presence of a macroscopic residual tumor after resection (p = 0.015) and metastasis at any time during follow-up (p < 0.0001) were each significant predictors of overall survival. All of these risk factors were associated with shorter survival. In a multivariate analysis of the operative cohort, only metastasis had a significant prognostic impact on overall survival (p < 0.0001). Notably, Ki-67, mitotic rate, and lymph node involvement as determined by surgical pathology were not significantly associated with overall survival for the patients who underwent surgical resection.
Impact of Surgical Resection on Overall and Disease-Specific Survival
Based on previous reports, particularly large populational studies, we hypothesized that in analyzing nonfunctioning PNETs across a broad array of clinicopathologic characteristics, surgical resection is likely to have a significant prognostic effect on survival. To assess this, the independent effect of resection on overall and disease-specific survival was analyzed using multivariable models. Indeed, across all patients with nonfunctioning PNETs (N = 249), surgical resection was a significant positive prognostic factor for overall survival (HR 0.375, p = 0.014), after controlling for metastasis, tumor size, and CACI. The effect of resection on survival was further tested using disease-specific survival: across all patients (N = 249), resection was also a significant positive prognostic factor for disease-specific survival (HR 0.249, p = 0.013), after controlling for tumor size and CACI. Metastasis was not included in the disease-specific survival model because metastatic disease was present in every patient who died of the PNET. Thus, consistent with previous studies, surgical resection of nonfunctioning PNETs is associated with improved survival when analyzed across a diverse population of patients.
Role of Surgical Resection in the Setting of Small Nonfunctioning PNETs
A more specific and contested question is whether small, localized, nonfunctioning PNETs should be resected. To address this, a more detailed analysis was conducted focusing on patients with small tumors ≤2.5 cm and no metastasis at presentation. Interestingly, in this subgroup of patients (n = 124), there was a significant statistical interaction between tumor size and an operation (p = 0.047), indicating that tumor size modifies the effect of an operation on overall survival. Thus, a systematic exploratory analysis was performed to determine the effect of an operation on overall survival at a series of tumor sizes ranging from 0.5 to 2.5 cm, in 0.5-cm increments, and the findings are detailed in Table 4 . An operation became a significant prognostic factor for overall survival when tumor size was 1.5 cm or larger (p = 0.050 or less for larger tumors) but was not significant in predicting overall survival for tumors under 1.5 cm (p = 0.317 or more for smaller tumors), controlling for CACI. Additionally, the hazard ratio associated with an operation decreased consistently with increased tumor size, indicating that an operation had the greatest therapeutic effect when the resected tumors were large. Among patients who underwent an operation and had a nonfunctioning PNET ≤2.5 cm without distant metastasis at presentation, five had lymph node involvement at the time of their operation, as determined by surgical pathology. These included one patient with a primary tumor ≤1 cm in size and four patients with tumors >1 and ≤2.5 cm in size. Additionally, over the course of follow-up, seven of the resected patients in this group developed distant metastasis. Two of these patients developed metastasis within 1 year of the operation, another one within 2 years, and the other four within 4 to 6 years. All seven of these patients whose disease recurred had tumors that were at least 1.5 cm in size at the time of their operation. Notably, lymph node involvement was not initially identified in six of the seven patients who developed distant metastasis post-operatively, and many of the patients who had lymph node involvement at the time of their operation did not go on to develop distant metastasis, including all of the patients with tumors ≤1.5 cm in size.
Most patients with small, localized nonfunctioning PNETs who died during the study period did so from causes unrelated to the PNET. There were no confirmed deaths by PNET among patients with tumors ≤2.5 cm with no metastasis at presentation, though one patient in each of the nonoperative and operative groups died of unknown causes. While some patients with small, localized tumors who died had a notably high CACI at presentation (>6), other patients who died during follow-up from a cause other than the PNET had a low CACI at presentation. The median CACI at presentation among patients who died in each group was 4 among the resected patients who died and 5 among the observed patients who died, which is only slightly higher than the median CACI of the groups overall. Future studies will be needed to assess if and how exactly the CACI should be used in considering the course of management for nonfunctioning PNETs.
Discussion
The malignant potential of nonfunctioning PNETs is difficult to predict, and the natural history of these tumors is not fully understood. However, tumor size has been consistently shown to be associated with metastatic risk and long-term survival, 12 , 14 , 17 and as such is an important component of staging according to WHO criteria. Clinically, when a small, nonfunctioning PNET is identified, it is difficult to know whether it represents detection of an early-stage malignant tumor with aggressive biology or a slow-growing benign tumor. Hence, the appropriate course of treatment for small, nonfunctioning tumors is hotly debated.
Our analysis revealed that surgical resection of nonfunctioning PNETs is independently and significantly associated with a longer overall and disease-specific survival across a broad array of patients, after adjusting for metastasis, tumor size, age, and comorbidities. However, for the subset of patients with small, localized nonfunctioning PNETs, the therapeutic effect of an operation is modified by tumor size. Among these patients, resection of nonfunctioning PNETs over 1.5 cm is significantly associated with a longer survival. However, resecting PNETs under 1.5 cm does not improve survival in our analysis. Additionally, though it was found that one patient who underwent surgical resection with a primary tumor ≤1 cm in size had lymph node involvement based on surgical pathology, this patient did not go on to develop distant metastasis over the course of follow-up. All patients whose disease recurred following resection had primary tumors that were at least 1.5 cm, and there was no clear link between nodal disease at the time of resection and the later development of distant metastases among resected patients. In totality, these findings suggest that localized tumors under 1.5 cm in size are likely to have low malignant potential. These results are consistent with those of a small prospective study conducted in Japan by Kishi and colleagues, which found that nonfunctioning PNETs that are 1.5 cm and under in size can be safely observed. 17 Over a median follow-up period of 45 months, none of their observed patients with tumors ≤1.5 cm experienced any lymph node or distant metastasis as detected by US and CT imaging at 6-monthly intervals. On the other hand, another recent report by Sharpe and colleagues using data from the National Cancer Data Base (NCDB) found that surgical resection of PNETs ≤2 cm was associated with an overall survival advantage compared to observation, independent of age, comorbidities, tumor grade, and treatment with nonsurgical therapies. 16 It is possible that the therapeutic effect of an operation increases markedly from tumor sizes of 1.5 to 2 cm-consistent with our findings of varying effects of surgery with incremental changes in tumor size-and that with a global analysis of the ≤2-cm group, these variations were not detected. Additionally, it is possible that the patient population in the NCDB did not capture all PNET patients, given potential differences in reporting practices across institutions. In particular, patients with substantial comorbidities and an incidental finding of a PNET may not have been well represented, as over 50 % of the study population had a Charlson score of 0. Nevertheless, the varying findings between studies highlight the need for additional research and indicate that tumor size, while influential, is clearly not the only factor that determines the effect of an operation on long-term prognoses.
Given the current findings, we propose that the exact tumor size should be factored into management decisions for small, localized nonfunctioning PNETs, along with patient age, comorbidities, metastasis status, and, of course, patient preferences. Our findings reveal a benefit to surgical resection for PNETs over 1.5 cm in size. However, for patients with tumors under 1.5 cm, the lack of demonstrated benefit needs to be weighed against the risks associated with pancreatic operations; therefore, many of these patients may be better served by regular, careful observation.
Primary Discussant
Steven J. Hughes, MD (Gainesville, FL) I want to congratulate the authors on a clearly presented study and the forthcoming well-written manuscript. Thank you for providing a copy of it to me in advance.
So what should we do about the incidental finding on computerized tomography of a small, enhancing lesion in the pancreas? A small percentage of these lesions will ultimately threaten the patient's life, but most will not. With the very rare exception of the small-cell variant of PNET, most small PNETs appear to lack metastatic potential, and even those lesions that ultimately metastasize progress slowly over a significant time frame. We lack sufficient tools to predict this more threatening natural history, and while pancreatic surgery has become increasingly safer, it is far from perfect.
Last year, at this meeting, the University of Chicago group led by Marshall Baker presented an analysis of the NCDB, concluding that resection conferred a survival benefit over observation for PNETs ≤2 cm. This is a wonderful study to follow, with clinical data from a single center. It improves our understanding of the management of PNETs, but the debate will continue. One can conclude from the data presented today that observation of PNETs ≤1.5 cm is as safe as operation.
To me, the greatest confounding variable impacting the ability to draw conclusions from this data is surgical judgment, and the group behind this study has this concept in abundance. Consistent with this, none of the deaths in the observation cohort can be attributed to the PNET. Yet, the Charlson age comorbidity index does not differ between the groups. There must be bias in this study introduced by the surgeon's judgment to operate versus observe that the CACI cannot capture. Further, there are many clinical details not accounted for in the presented data and not driven by comorbidities or age that may have factored into this decision that do not lend themselves to a table or a sample size amenable to a subgroup analysis, for example a lesion deep in the head of the pancreas versus a lesion Bhanging^off the body of the pancreas.
So, I applaud the authors on a provocative study of great importance to pancreatic surgeons, but caution the audience about over interpretation of the data.
I have two questions for the group: 1. Please speculate on why you did not observe an association between survival and proliferation rates or lymph node metastases.
2. What is the current algorithm for management of PNET at your institution, and what is your current recommendation regarding imaging modality and timing of follow-up for those patients placed into observation?
Closing Discussant
Dr. Zhang 1. Please speculate on why you did not observe an association between survival and proliferation rates or lymph node metastases.
Within the surgically resected group, we were also surprised to find a lack of significant association between overall survival and Ki-67 proliferative index and between overall survival and lymph node involvement at the time of the operation. One potential reason that Ki-67 was not a significant prognostic factor in this analysis may be that this study spanned a large number of years in order to include an adequate number of patients for this rare condition, and that particularly for patients from the earlier years, the surgical pathology either did not include Ki-67 or was performed by pathologists who did not specialize in pancreatic conditions. Of note, as part of another study currently being done by our group, surgical pathology specimens are being re-evaluated by pancreas-specialist pathologists and we are finding that many Ki-67 values have changed with the re-evaluation. With regard to lymph node involvement, previous reports have varied as to whether or not lymph node metastases are significant prognostic factors for long-term survival. In a validation study of different PNET staging systems, Ellison et al. 18 found that including lymph node status did not significantly improve survival prognostication.
At our institution, we generally follow patients with asymptomatic nonfunctioning PNETs with serial CT imaging, starting with one at 6 months and then every year thereafter for 5 years. If there is no tumor growth seen over this period, then the imaging is spaced out to every 2 years. Additionally, depending on the patient's age and comorbidities, which may suggest that they cannot tolerate a pancreatic operation, then we may not continue to scan them or space out the scans to every 2 years. Further studies, ideally prospective in nature, will be needed to determine the optimal protocol for following PNET patients.
